Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKesson
Boehringer Ingelheim
Johnson and Johnson
Moodys

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021131

See Plans and Pricing

« Back to Dashboard

NDA 021131 describes ZYVOX, which is a drug marketed by Pharmacia And Upjohn and is included in three NDAs. It is available from three suppliers. There are two patents protecting this drug and four Paragraph IV challenges. Additional details are available on the ZYVOX profile page.

The generic ingredient in ZYVOX is linezolid. There are twenty-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the linezolid profile page.
Summary for 021131
Tradename:ZYVOX
Applicant:Pharmacia And Upjohn
Ingredient:linezolid
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 021131
Medical Subject Heading (MeSH) Categories for 021131
Suppliers and Packaging for NDA: 021131
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZYVOX linezolid SOLUTION;INTRAVENOUS 021131 NDA Pharmacia and Upjohn Company LLC 0009-4992 0009-4992-02 10 BAG in 1 BOX (0009-4992-02) > 300 mL in 1 BAG (0009-4992-01)
ZYVOX linezolid SOLUTION;INTRAVENOUS 021131 NDA Pharmacia and Upjohn Company LLC 0009-5137 0009-5137-04 10 BAG in 1 BOX (0009-5137-04) > 100 mL in 1 BAG (0009-5137-01)
Paragraph IV (Patent) Challenges for 021131
Tradename Dosage Ingredient NDA Submissiondate
ZYVOX SOLUTION;INTRAVENOUS linezolid 021131 2009-12-29
ZYVOX SOLUTION;INTRAVENOUS linezolid 021131 2009-09-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength200MG/100ML (2MG/ML)
Approval Date:Apr 18, 2000TE:APRLD:Yes
Patent:  Start TrialPatent Expiration:Jul 29, 2021Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;INTRAVENOUSStrength400MG/200ML (2MG/ML)
Approval Date:Apr 18, 2000TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Jul 29, 2021Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength600MG/300ML (2MG/ML)
Approval Date:Apr 18, 2000TE:APRLD:Yes
Patent:  Start TrialPatent Expiration:Jul 29, 2021Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Merck
Baxter
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.